News Archive

September 2018

• Press Release Sep 21, 2018

  Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

  Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
• Press Release Sep 21, 2018

  Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe

  Children and adolescents with multiple sclerosis (MS) experience more frequent and often more severe relapses than adults with the disease, hindering their development and ability to take part in…
• Press Release Sep 21, 2018

  Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

  If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease   Children and adults…
• Press Release Sep 17, 2018

  World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime

  From a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1]  79% are willing…
• Press Release Sep 17, 2018

  Launch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care Professionals

  Alcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,…
• Press Release Sep 13, 2018

  Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients

  Real-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th…
• Press Release Sep 12, 2018

  Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS

  Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
• Press Release Sep 12, 2018

  Novartis survey shows psoriasis patients want treatment effect beyond clear skin

  New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
• Press Release Sep 11, 2018

  Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis

  Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has…
• Press Release Sep 11, 2018

  Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz

  Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg…
• Press Release Sep 11, 2018

  Alcon confirme son engagement envers la Suisse en perspective de la scission proposée avec Novartis

  Le siège social mondial sera basé à Genève à côté du bureau régional d'Alcon pour l'Europe, le Moyen-Orient et l'Afrique La société Alcon cotée en bourse sera enregistrée à Fribourg, où Alcon…
• Ad-hoc Releases Sep 06, 2018

  Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

  Novartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…